Taysha Gene Therapies reported progress in its TSHA-102 gene therapy for Rett syndrome, reaffirming FDA alignment on trial design and potential approval based on a six-month interim analysis from the REVEAL pivotal trial. The company is advancing dosing in the REVEAL and ASPIRE trials, expecting to complete dosing by Q2 2026, with longer-term safety and efficacy data due soon. TSHA-102 continues to show a favorable safety profile with no serious adverse events related to treatment. Financially, Taysha posted a net loss of $42.4 million for Q1 2026 but holds $276.6 million in cash, sufficient to fund operations into 2028. The company plans to complete a BLA-enabling manufacturing campaign by Q4 2026 and aims for regulatory submission based on ongoing trial data.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Immuron Limited announced a 6% increase in global sales for FY26, reaching AUD$7.7 million, driven by a 10% rise in Australian sales and significant growth in Canada and the US markets. The growth in Australia is attributed to enhanced digital market...
GRAVITY Co., Ltd. has officially launched Ragnarok: The New World, an open-world MMORPG based on the popular Ragnarok IP, in Southeast Asia on July 16, 2026. The game is available on both Mobile (Google Play and Apple App Store) and PC (official webs...
Zymeworks Inc. will release its second quarter 2026 financial results after market close on August 6, 2026. The company will not hold an earnings call following the release due to its pending acquisition of Theravance Biopharma. This acquisition will...
Global Net Lease, Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 5 after the NYSE closes. The company will hold a conference call and webcast on August 6 at 11:00 a.m. ET to discuss the res...
